Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Astrazeneca (AZNCF) EBITDA (2016 - 2025)

Historic EBITDA for Astrazeneca (AZNCF) over the last 16 years, with Q4 2025 value amounting to $2.8 billion.

  • Astrazeneca's EBITDA rose 260360.36% to $2.8 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $12.9 billion, marking a year-over-year increase of 10725.85%. This contributed to the annual value of $12.9 billion for FY2025, which is 10727.45% up from last year.
  • Astrazeneca's EBITDA amounted to $2.8 billion in Q4 2025, which was up 260360.36% from $2.6 billion recorded in Q3 2025.
  • In the past 5 years, Astrazeneca's EBITDA ranged from a high of $4.0 billion in Q1 2025 and a low of -$974.0 million during Q3 2022
  • Over the past 5 years, Astrazeneca's median EBITDA value was $1.6 billion (recorded in 2022), while the average stood at $1.3 billion.
  • As far as peak fluctuations go, Astrazeneca's EBITDA tumbled by 19515.15% in 2022, and later skyrocketed by 260360.36% in 2025.
  • Quarter analysis of 5 years shows Astrazeneca's EBITDA stood at -$746.0 million in 2021, then soared by 329.62% to $1.7 billion in 2022, then increased by 3.91% to $1.8 billion in 2023, then plummeted by 106.24% to -$111.0 million in 2024, then skyrocketed by 2603.6% to $2.8 billion in 2025.
  • Its last three reported values are $2.8 billion in Q4 2025, $2.6 billion for Q3 2025, and $3.6 billion during Q2 2025.